Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
7.92M
-
Shares change
-
-1M
-
Total reported value, excl. options
-
$12.2M
-
Value change
-
-$1.96M
-
Put/Call ratio
-
1.21
-
Number of buys
-
18
-
Number of sells
-
-24
-
Price
-
$1.54
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2022
62 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q3 2022.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.92M shares
of 66.6M outstanding shares and own 11.9% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.94M shares), Artal Group S.A. (750K shares), BlackRock Inc. (749K shares), Laurion Capital Management LP (722K shares), RENAISSANCE TECHNOLOGIES LLC (422K shares), GEODE CAPITAL MANAGEMENT, LLC (414K shares), MORGAN STANLEY (376K shares), DEUTSCHE BANK AG\ (224K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (206K shares), and CITADEL ADVISORS LLC (200K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.